论文部分内容阅读
As the first monoclonal antibody against vascular endothelial growth factor(VEGF), bevacizumab(BEV) is a definitely controversial antiangiogenic therapy in breast cancer. The initial excitement over improvements in progression-free survival(PFS) with BEV